aripiprazole (Abilify)

How long the trials actually ran

The longest trial behind the aripiprazole approval ran 3 weeks.

The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.

How many Americans take aripiprazole

Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.

8,246,931

prescriptions in the United States (2024)

1,780,154

people filling them (2024)

Prescriptions are up 26% since 2014. Whatever you decide about aripiprazole, you are deciding alongside about 1,780,154 other people this year.

Source: ClinCalc DrugStats (Medical Expenditure Panel Survey (MEPS), Agency for Healthcare Research and Quality), CC BY-SA 4.0, release 2026.08.

What people report to the FDA about aripiprazole

125,626

reports mentioning aripiprazole, all time

81,830

filed as serious (a report-level flag covering every drug and outcome in the report)

Source: FDA Adverse Event Reporting System (FAERS), via openFDA, data through 2026-07-30.

Known interactions, from the label

The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.

FDA label for aripiprazole, effective July 31, 2026 — DailyMed.

Who pays for aripiprazole

Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.

Medicare Part D

Read the under-65 group correctly before the numbers: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error. The beneficiary total sums brand-level rows, so treat it as an upper bound on distinct people. 683,829 beneficiaries filled 4,109,192 claims in 2024 — 347,000 aged 65 and over, and 336,829 under 65.

Medicaid

At least 4,973,266 prescriptions in 2024 — a floor, because 303 of 1,651 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.

All payers (survey estimate)

The MEPS-based estimate above puts the whole country at 8,246,931 prescriptions and 1,780,154 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.

The population nobody counts

The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of aripiprazole specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.

Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.

The approval, step by step

1. Step 1

   What the approval was actually based on

   Which studies did the FDA rely on, how long did they run, and who was in them?

   Efficacy of ABILIFY was established in the following adequate and well-controlled trials: Four short-term trials and one maintenance trial in adult patients... The efficacy of ABILIFY as monotherapy in the acute treatment of manic episodes was established in four 3-week, placebo-controlled trials in hospitalized patients who met the DSM-IV criteria for bipolar I disorder with manic or mixed episodes.

   FDA-approved labelling, 14 CLINICAL STUDIES — read the label on DailyMed

   Our reading

   The mania indication rests on four three-week trials in hospitalised patients. Read that against how the drug is actually used: for years, by outpatients, often as an add-on for depression. Three weeks in hospital and three years at home are not the same experiment.

2. Step 2

   The approval

   When was it approved, under what application, and by whose review?

   Approved

   November 15, 2002

   Application

   NDA021436

   Review

   STANDARD

   Original sponsor

   Otsuka

   Holds it now

   Otsuka

   Label submissions since

   42

   Source: openFDA Drugs@FDA, original application ORIG-1

3. Step 3

   What was added after it was on the market

   Which warnings arrived only after millions of people were already taking it?

   • Antipsychotics raise the risk of death in older people with dementia

     This is one of the clearest harm signals in psychiatric medicine, and it applies to a specific group: older adults with dementia-related psychosis. Pooling 17 placebo-controlled trials covering 5,106 patients over roughly 10 weeks, the risk of death was 1.6 to 1.7 times higher on an antipsychotic than on placebo — about 4.5% against 2.6%. Most deaths were cardiovascular or infectious, chiefly heart failure, sudden death and pneumonia.

     The FDA first applied this warning to the newer antipsychotics in 2005 and extended it to the older ones in 2008. No antipsychotic is approved for dementia-related psychosis.

     If this is being prescribed for an older relative with dementia, worth asking: what specific behaviour are we treating, what have we tried that is not a drug, what is the shortest time we can plan for, and when will we review stopping.

     RISPERDAL (risperidone) prescribing information — Boxed Warning: Increased Mortality in Elderly Patients with Dementia-Related Psychosis — U.S. Food and Drug Administration (approved labelling)

4. Step 4

   What independent research has found since

   What has been learned by people who were not selling it?

   • Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode…

     17 years after approval

     Across 402 randomized trials with 53,463 people, all 32 antipsychotics including aripiprazole reduced schizophrenia symptoms more than placebo; drugs differed more in side-effects than in effectiveness, and aripiprazole was one of only five drugs that significantly improved quality of life versus placebo (SMD -0.49).

     Worth asking

     Since antipsychotics differ more in side-effects than in how well they work, which side-effects was aripiprazole chosen to avoid in my case?

     Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis — Huhn M, et al. (2019)

   • Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic…

     18 years after approval

     Pooling 100 randomized trials with 25,952 people, aripiprazole was among the antipsychotics with the most favorable metabolic profile (least weight gain and blood-sugar/cholesterol change), while olanzapine and clozapine caused the most metabolic disturbance.

     Worth asking

     Aripiprazole is one of the gentler antipsychotics on weight and blood sugar — should we still schedule regular weight and lab checks, and how often?

     Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis — Pillinger T, et al. (2020)

   • Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression

     21 years after approval

     In 619 adults aged 60 or older with treatment-resistant depression (the OPTIMUM trial), adding aripiprazole to the current antidepressant improved well-being more than switching to bupropion (a 4.83- vs 2.04-point gain over 10 weeks) and led to remission in 28.9% of the aripiprazole group.

     Worth asking

     Before switching my antidepressant, is adding a low dose of aripiprazole to what I already take a better next step for me?

     Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression — Lenze EJ, et al. (2023)

   • Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant…

     13 years after approval

     In 181 adults aged 60 or older whose depression had not remitted on an antidepressant, adding aripiprazole led to remission in 44% versus 29% with placebo, but caused akathisia (restlessness) in 26% versus 12%.

     Worth asking

     If we add aripiprazole to my antidepressant, what is the plan for catching restlessness (akathisia) or tremor early, and what would we do then?

     Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial — Lenze EJ, et al. (2015)

   • Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized…

     7 years after approval

     Pooling 16 placebo-controlled trials with 3,480 patients, adding an atypical antipsychotic such as aripiprazole to an antidepressant roughly doubled the odds of depression remission (OR 2.00), but dropout because of side-effects was nearly four times more likely than with placebo (OR 3.91).

     Worth asking

     Add-on antipsychotics help more people reach remission but are harder to tolerate — how long a trial would we give aripiprazole before deciding whether to keep it?

     Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials — Nelson JC, Papakostas GI (2009)

   • The aripiprazole and gambling link, and why this particular study is weak evidence for it

     19 years after approval

     Aripiprazole acts on dopamine differently from other antipsychotics, and reports of new compulsive gambling on it have accumulated for years. Swedish researchers took every person in the country diagnosed with pathological gambling between 2005 and 2019 — 3,689 people — matched each to two people of the same age and sex from the general population, and looked at what had been prescribed to all 11,067.

     Within the subgroup who had schizophrenia or a related psychotic disorder, an aripiprazole prescription was associated with a gambling diagnosis at an odds ratio of 3.4. Dopamine agonists like pramipexole and ropinirole showed a similar pattern, at 3.2.

     Now the reasons to hold this loosely. The study has no time dimension: it can see that a person had both a prescription and a diagnosis, but not which came first, so it cannot show the medication preceded the gambling. The raw percentages in the paper look alarming — 88.8% against 71.2% — but that is an artefact of how the sample was built, since a third of it has gambling disorder by design; the odds ratio is the number that means something. And the subgroup the aripiprazole result comes from is small and heavily selected.

     This is a signal, consistent with a lot of case reports and with the drug's pharmacology. It is not proof, and the study design is the reason why.

     Worth asking

     Has anything about my spending, gambling, shopping or sexual behaviour changed since I started this, and is that something we should be tracking.

     Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden — Wolfschlag M, Håkansson A (2021)

5. Step 5

   What still is not known

   Which questions you might reasonably have has nobody answered yet?

   • Hospitalised patients under supervision for three weeks — what does that tell you about outpatient use over years?
   • Metabolic effects and tardive dyskinesia accumulate over time horizons far longer than any pivotal trial.
   • The dementia-mortality boxed warning applies to this class and came from post-market data, not from the approval package.